EKF Diagnostics' broker updated revenue and earnings forecasts for the financial year ending December 2011 and 2012 following its £13 million acquisition of Stanbio. EKF now has a US distribution and revenue platform as well as a distribution deal with Alere.
EKF has also increased investments into new facilities in Poland and Germany and product development. The updated broker projections are:
Adjusted EPS estimates for 2011, 2012 and 2013E are -1.43p, -0.13p and 0.62p (from 0.42p, 1.03p and 1.64p) respectively. The broker sees significant revenue and profit opportunities for the new business and has upgraded its target price to 74p from 65p.
The EKF share price has increased by 35% over the past year.
EKF Diagnostic Holdings Plc is currently graded C by LCF Research. To learn more, follow the link.
